Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas
  
Bristol places big bet on BioNTech's PD-L1xVEGF bispecific candidate • Source: Shutterstock

More from Deals

More from Therapy Areas